ReviewClinical and experimental medicine2025
A unifying model for multiple sclerosis.
Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A telomere-lipid-immunity axis linking viral integration to autoimmune disease risk.GeroScience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a complex neurodegenerative disorder with unresolved cause that has been the subject of intensive research. A variety of putative models have been proposed to explain the course of disease. The preeminent mechanisms are suggested to be based on autoimmunity, including via viral epitope mimicry, although difficulties with a classical autoimmunity model for MS have been described. One prior idea that incorporates consideration of viral-self-cross-reactivity is that reactivated HHV-6A virus might induce subsequent reactivation of another virus, EBV, in a relay, resulting in a cascade of downstream consequences. Here, an alternative model for MS is proposed. This posits a viral reactivation relay in which EBV reactivation in the brain precedes HHV-6A reactivation in oligodendrocytes and neurons. At this juncture, relapsing-remitting MS (RRMS) can ensue to generate characteristic lesions, dominated by outbreaks of viral reactivation and CD8+T-cell-mediated cytotoxicity and inflammation. Additionally, self-targeting antibodies can be raised to mark the onset of progressive MS in a subset of patients. This model harmonises a plethora of prior evidence from diverse fields. It is suggested that future studies should challenge this new model for MS and that it provides direction for future approaches to prevention and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.